Postoperative Follow-up And Chemotherapy Outcome In Borderline Ovarian Tumor

Objective: To evaluate the clinical outcomes of postoperative follow-up and chemotherapy by analyzing various factors related to borderline ovarian tumors.Methods: We retrospectively enrolled 127 patients with BOTs who received treatment and followed up in our center from January 2008 to December 2016 in our hospital(First affiliated hospital of soochow university).The age,reproductive history,tumor markers,selection of treatment methods,pathological types of postoperative tumors and pathological stages of tumor were analyzed.The postoperative tumor markers,tumor recurrence,survival prognosis and postoperative pregnancy were followed up.Postoperative recurrence and prognosis in patients with all may affect the cohort study of statistics and analysis of relevant factors,discussed the satisfaction of various treatments on patients with different demands and treatment outcome evaluation.Result: All the 127 patients with borderline ovarian tumors(BOTs)were treated with surgery,with an average age of 42.09 years(16 to 83 years).Among them,71 patients chose to fertility-sparing surgery(FSS).Fifty-six patients underwent radical surgery for ovarian tumors(RS).Among the 127 patients,12 patients had tumor recurrence(9.4%).Rates of recurrence did not significantly differ between the FSS(11.3%)and RS groups(7.1%;p=0.430).The recurrence rate of BOTs in patients with previous reproductive history was significantly lower than that of those who were not pregnant(p=0.004,compared with those in clinical stages).However,after the operation of patients with fertility surgery,the recurrence of BOTs was not protective(p=0.189).In the advanced borderline ovarian tumor,the recurrence rate increased,but there was no statistically significant difference between clinical stage,stage ? recurrence rate was 7.8%,stage ? recurrence rate was 12.5%,the stage ?-? recurrence rate was 17.6%(p= 0.272).Stage ?–? patients postoperative chemotherapy did not extend the recurrence interval.However,29.17 percent(7/24)of patients with CA125 increased after chemotherapy effectively reduced the tumor marker CA125,and 25% of patients with CA125 decreased to normal levels,and the overall rate of decline was 39.09-95.62%.The 5-year survival rate was 100%.Conclusion: Patients with childbirth history before surgery shown lower recurrence rate than others,however,postoperative delivery has no protection on recurrence.Due to the fact that recurrence and prognosis were not found any difference between FSS and RS groups,FSS is recommended for young patients with BOTs.Chemotherapy regime can significantly reduce the level of serum CA125,which should regard as disease control after surgery.However,adjuvant chemotherapy did not decrease recurrence rate or improving prognosis,even not prolonged recurrence-free period in advanced stage.The recurrence rate of the tumor is significantly smaller than that of the patients with a history of fertility history,and the postoperative progeny has no protective effect on tumor recurrence.There is no difference in tumor recurrence and prognosis in the early patients with radical surgery and preservation of reproductive function,and the fertility-sparing surgery has been recommended for most young patients.Chemotherapy after surgery can significantly reduce serum CA125 levels,thus postoperative chemotherapy can benefit in some patients,however,chemotherapy for advanced patients did not reduce the recurrence of the tumor,also did not extend the tumor recurrence interval,for improving the prognosis of patients with role remains to be seen.